The Collateral Benefit of COVID-19 Mitigation Strategies on Influenza

J Am Board Fam Med. 2022 Jul-Aug;35(4):680-685. doi: 10.3122/jabfm.2022.04.210437.

Abstract

Introduction: The ongoing COVID-19 pandemic initiated the implementation of numerous disease mitigation strategies aimed to prevent transmission of the SARS-CoV-2. Given the similarity in mode of transmission, we posit that these strategies have also had a collateral benefit in minimizing the transmission of influenza during the 2020 to 2021 season in California.

Methods: Five years of data including incidence of influenza-like illness (ILI), influenza hospitalization, and mortality related to influenza in California were analyzed.

Results: In each of these parameters, there was a marked decrease in influenza activity, suggesting the additional benefit of COVID-19 mitigation strategies on influenza prevention.

Discussion: Further study is recommended to determine which specific variables had greater impact on transmission of respiratory viruses, and therefore can be utilized to prevent future outbreaks of respiratory illness.

Keywords: COVID-19; California; Influenza; Pandemics; SARS-CoV-2.

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Humans
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Pandemics / prevention & control
  • SARS-CoV-2
  • Virus Diseases*